CBER/CDER Oncology Divisions Will Remain Separate, FDA Confirms

Maintaining separate oncology review teams for drugs and biologics will help to ensure a "smooth" transition in the reorganization of CBER and CDER, Office of New Drugs Deputy Director Sandra Kweder, MD, said Dec. 11

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet